Last reviewed · How we verify
AZM X mg + AML Y mg
AZM (azilsartan) is an angiotensin II receptor blocker and AML (amlodipine) is a calcium channel blocker; together they reduce blood pressure through complementary vasodilatory pathways.
AZM (azilsartan) is an angiotensin II receptor blocker and AML (amlodipine) is a calcium channel blocker; together they reduce blood pressure through complementary vasodilatory pathways. Used for Hypertension (essential hypertension in adults).
At a glance
| Generic name | AZM X mg + AML Y mg |
|---|---|
| Sponsor | Celltrion |
| Drug class | Angiotensin II receptor blocker + Calcium channel blocker combination |
| Target | AT1 receptor (azilsartan); L-type calcium channel (amlodipine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, while amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. This combination provides additive antihypertensive effects through dual mechanisms targeting the renin-angiotensin system and calcium-dependent vascular tone.
Approved indications
- Hypertension (essential hypertension in adults)
Common side effects
- Dizziness
- Headache
- Fatigue
- Peripheral edema
- Hyperkalemia (azilsartan component)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZM X mg + AML Y mg CI brief — competitive landscape report
- AZM X mg + AML Y mg updates RSS · CI watch RSS
- Celltrion portfolio CI